Aceso Life Science

Aceso Life Science Group Limited is a Hong Kong-listed investment holding company that has strategically pivoted toward the biotechnology and healthcare sectors. The company primarily focuses on regenerative medicine and cell-based therapies through its significant investments and collaborations, most notably with the Belgian cell therapy firm Promethera Biosciences. Aceso’s portfolio is centered on treating end-stage liver diseases, such as acute-on-chronic liver failure (ACLF) and urea cycle disorders, utilizing liver-derived stem cell technologies. The group's flagship platform, HepaStem, consists of liver-derived progenitor cells designed to reduce inflammation and fibrosis in damaged liver tissue. Beyond its biotech investments, Aceso maintains interests in financial services and property development, reflecting its origins as a diversified holding entity. The company aims to lead the commercialization of advanced regenerative therapies across the Asia-Pacific region.